المؤلفون: A. M. Lila, I. Z. Gaydukova, O. N. Anoshenkova, I. G. Bannikova, I. B. Vinogradova, M. L. Goldman, S. Yu. Davidian, L. P. Evstigneeva, O. E. Epifanova, E. V. Zemerova, A. I. Zagrebneva, L. V. Ivanova, A. K. Karibova, I. V. Menshikova, O. N. Mironenko, M. P. Mikhailova, N. E. Nikulenkova, I. M. Patrikeeva, T. V. Plaksina, G. R. Savvina, R. R. Samigullina, L. E. Sarantseva, J. V. Usacheva, O. P. Ukhanova, G. F. Fatkhullina, A. L. Chudinov, I. A. Shafieva, S. P. Yakupova, А. М. Лила, И. З. Гайдукова, О. Н. Аношенкова, И. Г. Банникова, И. Б. Виноградова, М. Л. Гольдман, С. Ю. Давидьян, Л. П. Евстигнеева, О. Е. Епифанова, Е. В. Земерова, А. И. Загребнева, Л. В. Иванова, А. К. Карибова, И. В. Меньшикова, О. Н. Мироненко, М. П. Михайлова, Н. Е. Никуленкова, И. М. Патрикеева, Т. В. Плаксина, Г. Р. Саввина, Р. Р. Самигуллина, Л. Е. Саранцева, Ю. В. Усачева, О. П. Уханова, Г. Ф. Фатхуллина, А. Л. Чудинов, И. А. Шафиева, С. П. Якупова

المساهمون: The article is sponsored by BIOCAD JSC, Статья спонсируется компанией АО «БИОКАД

المصدر: Modern Rheumatology Journal; Том 18, № 3 (2024); 32-43 ; Современная ревматология; Том 18, № 3 (2024); 32-43 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: ингибитор рецептора интерлейкина 6, rheumatoid arthritis, interleukin-6 receptor inhibitor, ревматоидный артрит

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1586/1470; Насонов ЕЛ, Олюнин ЮА, Лила АМ. Ревматоидный артрит: проблемы ремиссии и резистентности к терапии. Научно-практическая ревматология. 2018;56(3):263-71.; Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016 Oct 22; 388(10055):2023-2038. doi:10.1016/S0140-6736(16)30173-8. Epub 2016 May 3.; Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2019. 464 с.; Choy EH, De Benedetti F, Takeuchi T, et al. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020 Jun; 16(6):335-345. doi:10.1038/s41584-020-0419-z.; Favalli EG. Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis. Rheumatol Ther. 2020 Sep;7(3):473-516. doi:10.1007/s40744-020-00219-2.; Мазуров ВИ, Зоткин ЕГ, Гайдукова ИЗ и др. Эффективность и безопасность применения левилимаба в комбинации с метотрексатом у пациентов с ревматоидным артритом: результаты II фазы исследования AURORA. Научно-практическая ревматология. 2021;59(2):141-151.; Мазуров ВИ, Королев МА, Пристром АМ и др. Эффективность и безопасность левилимаба в сочетании с метотрексатом при лечении пациентов с активным ревматоидным артритом, устойчивым к монотерапии метотрексатом (двойное слепое рандомизированное плацебо-контролируемое исследование III фазы SOLAR). Современная ревматология. 2021; 15(4);13-23. doi:10.14412/1996-7012-2021-4-13-23; Мазуров ВИ, Лила АМ, Королев МА и др. Эффективность и безопасность левилимаба в комбинации с метотрексатом у пациентов с активным ревматоидным артритом: результаты 56 недель рандомизированного двойного слепого плацебо-контролируемого клинического исследования III фазы SOLAR. Научно-практическая ревматология. 2023;61(1):87-99.; Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep; 62(9): 2569-81. doi:10.1002/art.27584.; Schulz KF, Grimes DA. Multiplicity in randomised trials II: subgroup and interim analyses. Lancet. 2005 May;365(9471):1657-61. doi:10.1016/S0140-6736(05)66516-6.; Burmester GR, Rigby WF, van Vollenhoven RF, et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis. 2016 Jun;75(6):1081-91. doi:10.1136/annrheumdis-2015-207628. Epub 2015 Oct 28.; Burmester GR, Lin Y, Patel R, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. 2017 May;76(5):840-847. doi:10.1136/annrheumdis-2016-210310.; Bykerk VP, Ostor AJ, Alvaro-Gracia J, et al. Comparison of tocilizumab as monotherapy or with add-on disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice. Clin Rheumatol. 2015 Mar;34(3): 563-71. doi:10.1007/s10067-014-2857-y. Epub 2015 Jan 22.; Haraoui B, Jamal S, Ahluwalia V, et al. Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results From an Observational, Noninterventional Study. Rheumatol Ther. 2018 Dec;5(2): 551-565. doi:10.1007/s40744-018-0130-6. Epub 2018 Oct 28.; Загребнева АИ, Симонова ЕН, Мезенова ТВ и др. Московский опыт применения ингибиторов рецептора интерлейкина 6 в терапии ревматоидного артрита в условиях пандемии COVID-19. Современная ревматология. 2022;16(6):73-79. doi:10.14412/1996-7012-2022-6-73-79; Smolen JS, Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol. 2015 May;11(5):276-89. doi:10.1038/nrrheum.2015.8.; https://mrj.ima-press.net/mrj/article/view/1586

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1586
https://doi.org/10.14412/1996-7012-2024-3-32-43

المؤلفون: T. V. Korotaeva, E. E. Gubar, E. Yu. Loginova, Y. L. Korsakova, E. A. Vasilenko, I.-D. Yu. Ilyevsky, L. V. Ivanova, E. Yu. Akulinushkina, P. A. Shesternya, O. V. Matveychuk, Yu. Yu. Grabovetskaya, A. A. Barakat, M. A. Korolev, E. V. Zonova, O. A. Georginova, I. V. Kolotilina, I. M. Marusenko, I. B. Vinogradova, O. B. Nesmeyanova, N. E. Grigoriadi, A. V. Petrov, D. G. Krechikova, T. V. Kropotina, S. P. Yakupova, V. I. Mazurov, Т. В. Коротаева, Е. Е. Губарь, Е. Ю. Логинова, Ю. Л. Корсакова, Е. А. Василенко, И.-Д. Ю. Ильевский, Л. В. Иванова, Е. Ю. Акулинушкина, П. А. Шестерня, О. В. Матвейчук, Ю. Ю. Грабовецкая, А. А. Баракат, М. А. Королев, Е. В. Зонова, О. А. Георгинова, И. В. Колотилина, И. М. Марусенко, И. Б. Виноградова, О. Б. Несмеянова, Н. Е. Григориади, А. В. Петров, Д. Г. Кречикова, Т. В. Кропотина, С. П. Якупова, В. И. Мазуров

المساهمون: The article is sponsored by Novartis Pharma LLC., Статья спонсируется компанией Novartis Pharma.

المصدر: Modern Rheumatology Journal; Том 17, № 6 (2023); 22-30 ; Современная ревматология; Том 17, № 6 (2023); 22-30 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: тактика ведения, non-interventional study, diagnostics, treatment tactics, неинтервенционное исследование, диагностика

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1498/1411; Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017 Mar 9;376(10):957-970. doi:10.1056/NEJMra1505557.; Клинические рекомендации «Псориаз артропатический. Псориатический артрит», 2021 г. https://cr.minzdrav.gov.ru/recomend/562_2ysclid=ll9ayly1zm11831220; Корсакова ЮЛ, Логинова ЕЮ, Коротаева ТВ и др. Бремя прогрессирования псориатического артрита. Данные общероссийского регистра. Терапевтический архив. 2022;94(5):622-627.; de Vlam K, Lories R, Steinfeld S, et al. Is axial involvement underestimated in patients with psoriatic arthritis? Data from the BEPAS cohort. Arthritis Rheumatol. 2015 Oct:67 Suppl 10:1-4046. doi:10.1002/art.39448.; Feld J, Chandran V, Haroon N, et al. Axial disease in psoriatic arthritis and ankylosing spondylitis: A critical comparison. Nat Rev Rheumatol. 2018 Jun;14(6):363-371. doi:10.1038/s41584-018-0006-8.; Губарь ЕЕ, Логинова ЕЮ, Корсакова ЮЛ и др. Возможности скрининга высокого риска поражения осевого скелета при псориатическом артрите. Современная ревматология. 2020;14(3):34-38. doi:10.14412/1996-7012-2020-3-34-38; Губарь ЕЕ, Коротаева ТВ, Корсакова ЮЛ и др. Клинико-инструментальная характеристика поражения позвоночника при псориатическом артрите в реальной клинической практике. Научно-практическая ревматология. 2022;60(4):465-472.; Mease PJ, Palmer JB, Liu M, et al. Influence of axial involvement on clinical characteristics of psoriatic arthritis: Analysis from the corrona psoriatic arthritis/spondyloarthritis registry. J Rheumatol. 2018 Oct;45(10): 1389-1396. doi:10.3899/jrheum.171094. Epub 2018 Jul 1.; Stouten V, Pazmino S, Verschueren P, et al. Comorbidity burden in the first three years after diagnosis in patients with rheumatoid arthritis, psoriatic arthritis or spondyloarthritis: a general practice registry-based study. RMD Open. 2021 Jun;7(2):e001671. doi:10.1136/rmdopen-2021-001671.; Queiro R, Canete JD. Good clinimetric alignment between remission and a low impact of disease in patients with axial psoriatic arthritis. Clin Exp Rheumatol. 2020 Jan-Feb; 38(1):136-139. Epub 2019 Jul 19.; Gossec L. EULAR-Recommendations on the management of PsA. Presented at: EULAR 2023 Congress; May 31 to June 3, 2023, Milan, Italy; Coates LC, Corp N, van der Windt DA, et al. GRAPPA Treatment Recommendations: 2021 Update. J Rheumatol. 2022 Jun;49 (6 Suppl 1):52-54. doi:10.3899/jrheum.211331. Epub 2022 Mar 15.; Chandran V, Barrett J, Schentag CT, et al. Axial psoriatic arthritis: update on a longterm prospective study. J Rheumatol. 2009 Dec; 36(12):2744-50. doi:10.3899/jrheum.090412; Jadon DR, Sengupta R, Nightingale A, et al. Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis. Ann Rheum Dis. 2017 Apr;76(4):701-707. doi:10.1136/annrheumdis-2016-209853.; Gubar E, Korotaeva T, Korsakova Y, et al. Clinical and radiographic phenotype of axial psoriatic arthritis. Ann Rheum Dis. 2022;81(1): 1592. doi:10.1136/annrheumdis-2022- eular.1564; Губарь ЕЕ, Логинова ЕЮ, Смирнов АВ и др. Клинико-инструментальная характеристика аксиального поражения при раннем периферическом псориатическом артрите. (Данные исследования РЕМАРКА). Научно-практическая ревматология. 2018; 56(1):34-40.; Baraliakos X, Gossec L, Kane P, et al Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. 2021 May;80(5): 582-590. doi:10.1136/annrheumdis-2020-218808. Epub 2020 Dec 17.; https://mrj.ima-press.net/mrj/article/view/1498

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1498
https://doi.org/10.14412/1996-7012-2023-6-22-30

المؤلفون: A. M. Lila, L. I. Alekseeva, I. B. Belyaeva, I. B. Vinogradova, N. A. Demidova, O. V. Kalyuzhin, I. I. Nesterovich, V. N. Sorotskaya, L. Yu. Shirokova, S. P. Yakupova, А. М. Лила, Л. И. Алексеева, И. Б. Беляева, И. Б. Виноградова, Н. А. Демидова, О. В. Калюжин, И. И. Нестерович, В. Н. Сороцкая, Л. Ю. Широкова, С. П. Якупова

المساهمون: Статья спонсируется компанией ООО «НПО Петровакс Фарм».

المصدر: Modern Rheumatology Journal; Том 17, № 6 (2023); 136-142 ; Современная ревматология; Том 17, № 6 (2023); 136-142 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: босвеллиевые кислоты, gonarthrosis, ARTNEO, undenatured (native) type II collagen, oral immune tolerance, boswellic acids, гонартроз, Артнео, неденатурированный (нативный) коллаген II типа, оральная иммунная толерантность

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1514/1430; Yao Q, Wu X, Tao C, et al. Osteoarthritis: pathogenic signaling pathways and therapeutic targets. Signal Transduct Target Ther. 2023 Feb 3;8(1):56. doi:10.1038/s41392-023-01330-w.; Hawker GA, King LK. The Burden of Osteoarthritis in Older Adults. Clin Geriatr Med. 2022 May;38(2):181-192. doi:10.1016/j.cger.2021.11.005.; Favero M, Belluzzi E, Ortolan A, et al. Erosive hand osteoarthritis: latest findings and outlook. Nat Rev Rheumatol. 2022 Mar;18(3): 171-183. doi:10.1038/s41584-021-00747-3. Epub 2022 Feb 1.; Conaghan PG, Abraham L, Graham-Clarke P, et al. OP0190 Understanding current prescription drug treatment paradigms for patients with osteoarthritis in Europe. Ann Rheum Dis. 2020;79:118.; Namba RS, Inacio MC, Pratt NL, et al. Postoperative opioid use as an early indication of total hip arthroplasty failure. Acta Orthop. 2016 Jul;87 Suppl 1(Suppl 1):37-43. doi:10.1080/17453674.2016.1181820. Epub 2016 May 11.; Conley B, Bunzli S, Bullen J, et al. Core Recommendations for Osteoarthritis Care: A Systematic Review of Clinical Practice Guidelines. Arthritis Care Res (Hoboken). 2023 Sep;75(9):1897-1907. doi:10.1002/acr.25101. Epub 2023 Mar 17.; Резолюция консенсуса экспертов Российской Федерации по диагностике и лечению остеоартрита для врачей первичного звена. Терапия. 2022;8(5):119-128.; Honvo G, Lengele L, Charles A, et al. Role of Collagen Derivatives in Osteoarthritis and Cartilage Repair: A Systematic Scoping Review With Evidence Mapping. Rheumatol Ther. 2020 Dec;7(4):703-740. doi:10.1007/s40744-020-00240-5. Epub 2020 Oct 17.; Lugo JP, Saiyed ZM, Lane NE. Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study. Nutr J. 2016 Jan 29;15:14. doi:10.1186/s12937-016-0130-8.; Crowley DC, Lau FC, Sharma P, et al. Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial. Int J Med Sci. 2009 Oct 9;6(6):312-21. doi:10.7150/ijms.6.312.; Liu X, Machado GC, Eyles JP, et al. Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis. Br J Sports Med. 2018 Feb;52(3):167-175. doi:10.1136/bjsports-2016-097333. Epub 2017 Oct 10.; Nagler-Anderson C, Bober LA, Robinson ME, et al. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci U S A. 1986 Oct;83(19):7443-6. doi:10.1073/pnas.83.19.7443.; Milojevic D, Nguyen KD, Wara D, Mellins ED. Regulatory T cells and their role in rheumatic diseases: a potential target for novel therapeutic development. Pediatr Rheumatol Online J. 2008 Dec 1:6:20. doi:10.1186/1546-0096-6-20.; Tordesillas L, Berin MC. Mechanisms of Oral Tolerance. Clin Rev Allergy Immunol. 2018 Oct;55(2):107-117. doi:10.1007/s12016-018-8680-5.; Faria AM, Weiner HL. Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol. 2006 Jun-Dec; 13(2-4):143-57. doi:10.1080/17402520600876804.; Bagchi D, Misner B, Bagchi M, et al. Effects of orally administered undenatured type II collagen against arthritic inflammatory diseases: a mechanistic exploration. Int J Clin Pharmacol Res. 2002;22(3-4):101-10.; Collagenase and rheumatoid arthritis. N Engl J Med. 1968 Oct 24;279(17):942-3. doi:10.1056/NEJM196810242791710.; Mabbott NA, Donaldson DS, Ohno H, et al. Microfold (M) cells: important immunosurveillance posts in the intestinal epithelium. Mucosal Immunol. 2013 Jul;6(4):666-77. doi:10.1038/mi.2013.30. Epub 2013 May 22.; Pabst O, Mowat AM. Oral tolerance to food protein. Mucosal Immunol. 2012 May; 5(3):232-9. doi:10.1038/mi.2012.4. Epub 2012 Feb 8.; Wambre E, Jeong D. Oral Tolerance Development and Maintenance. Immunol Allergy Clin North Am. 2018 Feb;38(1):27-37. doi:10.1016/j.iac.2017.09.003. Epub 2017 Oct 26.; Lv Z, Yang YX, Li J, et al. Molecular Classification of Knee Osteoarthritis. Front Cell Dev Biol. 2021 Aug 27;9:725568. doi:10.3389/fcell.2021.725568.; National Academies of Sciences, Engineering, and Medicine. Developing Multimodal Therapies for Brain Disorders: Proceedings of a Workshop. Washington: The National Academies Press; 2017.; Mahajan R, Rathod NR, Narayanan V. (2019). Multimodal Anti-Inflammatory Approach to Osteoarthritis Management – Review of T Cell Immunomodulation with Undenatured (Native) Collagen Type II, and LOX Inhibition with Boswellia. Nov Tech Arthritis Bone Res. 2019;3(4):555618. doi:10.19080/NTAB.2019.03.555618.; Zapata A, Fernandez-Parra R. Management of Osteoarthritis and Joint Support Using Feed Supplements: A Scoping Review of Undenatured Type II Collagen and Boswellia serrata. Animals (Basel). 2023 Feb 27;13(5): 870. doi:10.3390/ani13050870.; Jain AV, Jain KA, Vijayaraghavan N. AflaB2® and Osteoarthritis: A Multicentric, Observational, Post-Marketing Surveillance Study in Indian Patients Suffering from Knee Osteoarthritis. Int J Res Orthop. 2021 Jan;7(1): 110-115. doi:10.18203/issn.2455-4510. IntJResOrthop20205570.; Sadigursky D, Sanches M, Garcia N, et al. Effectiveness of the use of non-hydrolysed type II collagen in the treatment of osteoarthritis: a systematic review and meta-analysis. Brazilian Journal of Health Review. 2023; 6(1):1649-1660. doi:10.34119/bjhrv6n1-131.; Yu G, Xiang W, Zhang T, et al. Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis. BMC Complement Med Ther. 2020 Jul 17;20(1):225. doi:10.1186/s12906-020-02985-6.; Cameron M, Chrubasik S. Oral herbal therapies for treating osteoarthritis. Cochrane Database Syst Rev. 2014 May 22;2014(5): CD002947. doi:10.1002/14651858. CD002947.pub2.; Gwinnutt JM, Wieczorek M, Rodriguez-Carrio J, et al. Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. RMD Open. 2022 Jun; 8(2):e002167. doi:10.1136/rmdopen-2021-002167.; Neogi T, Colloca L. Placebo effects in osteoarthritis: implications for treatment and drug development. Nat Rev Rheumatol. 2023 Oct;19(10):613-626. doi:10.1038/s41584- 023-01021-4. Epub 2023 Sep 11.; Wen X, Luo J, Mai Y, et al. Placebo Response to Oral Administration in Osteoarthritis Clinical Trials and Its Associated Factors: A Model-Based Meta-analysis. JAMA Netw Open. 2022 Oct 3;5(10):e2235060. doi:10.1001/jamanetworkopen.2022.35060.; Lane NE, Hochberg MC, Nevitt MC, et al. OARSI clinical trials recommendations: design and conduct of clinical trials for hip osteoarthritis. Osteoarthritis Cartilage. 2015 May;23(5):761-71. doi:10.1016/j.joca.2015.03.006.; https://mrj.ima-press.net/mrj/article/view/1514

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1514
https://doi.org/10.14412/1996-7012-2023-6-136-142

المؤلفون: L. N. Denisov, L. I. Alekseeva, E. G. Zotkin, I. S. Dydykina, A. M. Lila, S. S. Rodionova, A. Yu. Kochish, E. A. Trofimov, E. Z. Yakupov, S. P. Yakupova, L. N. Eliseeva, Л. Н. Денисов, Л. И. Алексеева, Е. Г. Зоткин, И. С. Дыдыкина, А. М. Лила, С. С. Родионова, А. Ю. Кочиш, Е. А. Трофимов, Э. З. Якупов, С. П. Якупова, Л. Н. Елисеева

المساهمون: This article has been supported by Viatris., Статья спонсируется компанией ООО «Виатрис».

المصدر: Modern Rheumatology Journal; Том 16, № 4 (2022); 80-87 ; Современная ревматология; Том 16, № 4 (2022); 80-87 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: метаанализ, osteoarthritis, knee joints, effectiveness of treatment, meta-analysis, остеоартрит, коленные суставы, эффективность лечения

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1327/1273; Centers for Disease Control and Prevention. What is osteoarthritis (OA)? https://www.cdc.gov/arthritis/basics/osteoarthritis.htm.; Mobasheri A, Batt M. An update on the pathophysiology of osteoarthritis. Ann Phys Rehabil Med. 2016 Dec;59(5-6):333-9. doi:10.1016/j.rehab.2016.07.004. Epub 2016 Aug 18.; Cross M, Smith E, Hoy D, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014 Jul;73(7):1323-30. doi:10.1136/annrheumdis-2013-204763. Epub 2014 Feb 19.; Bruyere O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019 Dec;49(3):337-50. doi:10.1016/j.semarthrit.2019.04.008. Epub 2019 Apr 30.; Bruyere O, Cooper C, Al-Daghri NM, et al. Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clin Exp Res. 2018 Feb; 30(2):111-7. doi:10.1007/s40520-017-0861-1. Epub 2017 Nov 24.; Saengnipanthkul S, Waikakul S, Rojanasthien S, et al. Differentiation of patented crystalline glucosamine sulfate from other glucosamine preparations will optimize osteoarthritis treatment. Int J Rheum Dis. 2019 Mar; 22(3):376-85. doi:10.1111/1756-185X.13068. Epub 2017 Mar 23.; Kucharz EJ, Kovalenko V, Szanto S, et al. A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes. Curr Med Res Opin. 2016 Jun;32(6):997-1004. doi:10.1185/03007995.2016.1154521. Epub 2016 Feb 26.; Bruyere O, Altman RD, Reginster JY. Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S12-7. doi:10.1016/j.semarthrit.2015.11.011. Epub 2015 Dec 2.; Reginster JY, Cooper C, Hochberg M, et al. Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis. Curr Med Res Opin. 2015 May;31(5):1041-5. doi:10.1185/03007995.2015.1027183. Epub 2015 Mar 24.; Herrero-Beaumont G, Rovati L. Use of crystalline glucosamine sulfate in osteoarthritis. Future Rheumatology. 2006;(1):397-414.; Цветкова ЕС, Иониченок НГ, Денисов ЛН. Современная фармакотерапия остеоартроза коленных суставов: особенности симптоматического и болезнь-модифицирующего действия. Сообщение 1. Особенности симптоматического действия современных препаратов при остеоартрозе коленных суставов. Научно-практическая ревматология. 2015;53(1):63-8.; Lila AM, Denisov LN, Zotkin EG, et al. Pharmacological Management of Osteoarthritis with a Focus on Symptomatic Slow-Acting Drugs: Recommendations from Leading Russian Experts. J Clin Rheumatol. 2021 Dec 1; 27(8):e533-e539. doi:10.1097/RHU.0000000000001507.; Eriksen P, Bartels EM, Altman RD, et al. Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: a metaanalysis of placebo-controlled trials. Arthritis Care Res (Hoboken). 2014 Dec;66(12): 1844-55. doi:10.1002/acr.22376.; Towheed TE, Maxwell L, Anastassiades TP, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005 Apr 18;2005(2):CD002946. doi:10.1002/14651858.CD002946.pub2.; Beaudart C, Lengele L, Leclercq V, et al. Symptomatic Efficacy of Pharmacological Treatments for Knee Osteoarthritis: A Systematic Review and a Network Meta-Analysis with a 6-Month Time Horizon. Drugs. 2020 Dec;80(18):1947-59. doi:10.1007/s40265-020-01423-8.; Gregori D, Giacovelli G, Minto C, et al. Association of Pharmacological Treatments With Long-term Pain Control in Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis. JAMA. 2018 Dec 25;320(24): 2564-79. doi:10.1001/jama.2018.19319.; Veronese N, Demurtas J, Smith L, et al. Glucosamine sulphate: an umbrella review of health outcomes. Ther Adv Musculoskelet Dis. 2020 Dec 26;12:1759720X20975927. doi:10.1177/1759720X20975927. eCollection 2020.; Tonin FS, Rotta I, Mendes AM, Pontarolo R. Network meta-analysis: a technique to gather evidence from direct and indirect comparisons. Pharm Pract (Granada). Jan-Mar 2017;15(1):943. doi:10.18549/PharmPract.2017.01.943. Epub 2017 Mar 15.; Gnylorybov AM, Ter-Vartanian SK, Golovach IY, et al. Expert Opinion on the Extensive Use of Prescription Crystalline Glucosamine Sulfate in the Multimodal Treatment of Osteoarthritis in Ukraine, Kazakhstan, Uzbekistan, and Armenia. Clin Med Insights Arthritis Musculoskelet Disord. 2020 Aug 4;13: 1179544120946743. doi:10.1177/11795 44120946743. eCollection 2020.; Rovati LC, Girolami F, Persiani S. Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties. Ther Adv Musculoskelet Dis. 2012 Jun;4(3):167-80. doi:10.1177/1759720X12437753.; Mbuagbaw L, Rochwerg B, Jaeschke R, et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Syst Rev. 2017 Apr 12;6(1):79. doi:10.1186/s13643-017-0473-z.; Gregori D, Giacovelli G, Minto C, et al. Association of Pharmacological Treatments With Long-term Pain Control in Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis. (Supplementary content). JAMA. 2018 Dec 25;320(24):2564-79. doi:10.1001/jama.2018.19319.; Jackson CG, Plaas AH, Sandy JD, et al. The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination. Osteoarthritis Cartilage. 2010 Mar;18(3):297-302. doi:10.1016/j.joca.2009.10.013. Epub 2009 Nov 10.; Tenti S, Giordano N, Mondanelli N, et al. A retrospective observational study of glucosamine sulfate in addition to conventional therapy in hand osteoarthritis patients compared to conventional treatment alone. Aging Clin Exp Res. 2020 Jun;32(6):1161-72. doi:10.1007/s40520-019-01305-4. Epub 2019 Aug 19.; Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008 Apr 26;336(7650): 924-6. doi:10.1136/bmj.39489.470347.AD.; Bruyere O, Cooper C, Pelletier JP, et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S3-11. doi:10.1016/j.semarthrit.2015.11.010. Epub 2015 Dec 2.; Da Costa BR, Reichenbach S, Keller N, et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network metaanalysis. Lancet. 2017 Jul 8;390(10090):e21-e33. doi:10.1016/S0140-6736(17)31744-0.; Gang D, Xiaguang C, Kanghua Y, et al. Combined effect of celecoxib and glucosamine sulfate on inflammatory factors and oxidative stress indicators in patients with knee osteoarthritis. Tropical Journal of Pharmaceutical Research. 2019;18(2):397-402.; Cheleschi S, Tenti S, Giannotti S, et al. A Combination of Celecoxib and Glucosamine Sulfate Has Anti-Inflamatory and Chondroprotective Effects: Results from an In Vitro Study on Human Osteoarthritic Chondrocytes. Int J Mol Sci. 2021 Aug 20;22(16):8980. doi:10.3390/ijms22168980.; Sun Y, Wang C, Gong C. Repairing effects of glucosamine sulfate in combination with etoricoxib on articular cartilages of patients with knee osteoarthritis. J Orthop Surg Res. 2020 Apr 16;15(1):150. doi:10.1186/s13018-020-01648-z.; Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001 Jan 27;357(9252):251-6. doi:10.1016/S0140-6736(00)03610-2.; Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M, et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum. 2007 Feb;56(2):555-67. doi:10.1002/art.22371.; Makhous R. Effectiveness and Safety of Glucosamine in the Treatment of Osteoarthritis. Research Journal of Pharmacy and Technology. 2018;11:489.; Pavelka K, Gatterova J, Olejarova M, et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2002 Oct 14;162(18): 2113-23. doi:10.1001/archinte.162.18.2113.; Honvo G, Reginster JY, Rabenda V, et al. Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs Aging. 2019 Apr;36(Suppl 1):65-99. doi:10.1007/s40266-019-00662-z.; Simon RR, Marks V, Leeds AR, Anderson JW. A comprehensive review of oral glucosamine use and effects on glucose metabolism in normal and diabetic individuals. Diabetes Metab Res Rev. 2011 Jan;27(1):14-27. doi:10.1002/dmrr.1150. Epub 2010 Dec 7.; Saghafi M, Karimi M, Bonakdaran S, Massoudnia N. Oral Glucosamine Effect on Blood Glucose and Insulin Levels in Patients With Non-Diabetic Osteoarthritis: A DoubleBlind, Placebo-Controlled Clinical Trial. Arch Rheumatol. 2016 Oct 1;31(4):340-5. doi:10.5606/ArchRheumatol.2016.5632. eCollection 2016 Dec.; Veronese N, Cooper C, Reginster JY, et al. Type 2 diabetes mellitus and osteoarthritis. Semin Arthritis Rheum. 2019 Aug;49(1):9-19. doi:10.1016/j.semarthrit.2019.01.005. Epub 2019 Jan 11.; Qiu GX, Gao SN, Giacovelli G, et al. Efficacy and safety of glucosamine sulfate versus ibuprofen in patients with knee osteoarthritis. Arzneimittelforschung. 1998 May; 48(5):469-74.; Cooper C, Chapurlat R, Al-Daghri N, et al. Safety of Oral Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Osteoarthritis: What Does the Literature Say? Drugs Aging. 2019 Apr;36(Suppl 1):15-24. doi:10.1007s40266-019-00660-1.; Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: metaanalyses of individual participant data from randomised trials. Lancet. 2013 Aug 31; 382(9894):769-79. doi:10.1016/S0140-6736(13)60900-9. Epub 2013 May 30.; Gunter BR, Butler KA, Wallace RL, et al. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a metaanalysis. J Clin Pharm Ther. 2017 Feb;42(1): 27-38. doi:10.1111/jcpt.12484. Epub 2016 Dec 26.; Caldwell B, Aldington S, Weatherall M, et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med. 2006 Mar;99(3):132-40. doi:10.1258/jrsm.99.3.132.; Al-Rashed F, Calay D, Lang M, et al. Celecoxib exerts protective effects in the vascular endothelium via COX-2-independent activation of AMPK-CREB-Nrf2 signalling. Sci Rep. 2018 Apr 19;8(1):6271. doi:10.1038/s41598-018-24548-z.; Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016 Dec 29;375(26):2519-29. doi:10.1056/NEJMoa1611593. Epub 2016 Nov 13.; Rovati LC, Girolami F, D'Amato M, Giacovelli G. Effects of glucosamine sulfate on the use of rescue non-steroidal anti-inflammatory drugs in knee osteoarthritis: Results from the Pharmaco-Epidemiology of GonArthroSis (PEGASus) study. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S34-41. doi:10.1016/j.semarthrit.2015.10.009. Epub 2015 Oct 29.; Bruyere O, Pavelka K, Rovati LC, et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebocontrolled trials. Osteoarthritis Cartilage. 2008 Feb;16(2):254-60. doi:10.1016/j.joca.2007.06.011. Epub 2007 Jul 27.; Scholtissen S, Bruyere O, Neuprez A, et al. Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with paracetamol. Int J Clin Pract. 2010 May;64(6):756-62. doi:10.1111/j.1742-1241.2010.02362.x.; Developing NICE guidelines: the manual. Process and methods. National Institute for Health and Care Excellence; 2014. https://www.nice.org.uk/process/pmg20/resources/developing-nice-guidelines-the-manual-pdf-72286708700869; Bruyere O, Reginster JY, Honvo G, Detilleux J. Cost-effectiveness evaluation of glucosamine for osteoarthritis based on simulation of individual patient data obtained from aggregated data in published studies. Aging Clin Exp Res. 2019 Jun;31(6):881-7. doi:10.1007/s40520-019-01138-1. Epub 2019 Feb 12.; https://mrj.ima-press.net/mrj/article/view/1327

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1327
https://doi.org/10.14412/1996-7012-2022-4-80-87

المؤلفون: L. I. Alekseeva, E. A. Taskina, N. G. Kashevarova, E. P. Sharapova, E. A. Strebkova, S. G. Anikin, N. V. Chichasova, T. A. Raskina, E. V. Zonova, E. N. Otteva, E. I. Shmidt, S. P. Yakupova, I. B. Vinogradova, O. N. Ivanova, V. A. Lila, B. V. Zavadovsky, P. A. Shesternya, A. M. Lila, Л. И. Алексеева, Е. А. Таскина, Н. Г. Кашеварова, Е. П. Шарапова, Е. А. Стребкова, С. Г. Аникин, Н. В. Чичасова, Т. А. Раскина, Е. В. Зонова, Э. Н. Оттева, Е. И. Шмидт, С. П. Якупова, И. Б. Виноградова, О. Н. Иванова, В. А. Лила, Б. В. Завадовский, П. А. Шестерня, А. М. Лила

المساهمون: Исследование выполнено в рамках научной темы № НИОКТР АААА-А19-119021190150-6 «Разработка методов комплексной терапии заболеваний костно-мышечной системы».

المصدر: Modern Rheumatology Journal; Том 15, № 1 (2021); 51-59 ; Современная ревматология; Том 15, № 1 (2021); 51-59 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: гликозаминогликан-пептидный комплекс, comorbidities, glycosaminoglycan-peptide complex, коморбидные заболевания

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1089/1073; Strauss WL Jr, Cave AJE. Pathology and the posture of Neanderthal man. Q Rev Biol. 1957 Dec;32(4):348-63. doi:10.1086/401979.; Heberden W. Commentaries on the History and Cure of Diseases. London: T. Payne; 1802.; Sandifort E. Museum Anatomicum Academiae Lugduno-Batavae. Vol. 2. Leiden: University of Leiden; 1793. Table LXIV.; Haygarth J. A clinical history of the nodosity of the joints. London: Gadell and Davies; 1805.; Brodie BC. Pathological and Surgical Observations on the Diseases of the Joints. 2nd ed. London: Longman, Hurst, Rees, Orne and Brown; 1822.; Garrod AE. A Treatise of Rheumatism and Rheumatoid Arthritis. London: Griffin; 1890.; Willy C, Schneider P, Engelhardt M, et al. Richard von Volkmann: surgeon and Renaissance man. Clin Orthop Relat Res. 2008 Feb;466(2):500-6. doi:10.1007/s11999-007-0007-4. Epub 2008 Jan 10.; Forsbrook WH. A Dissertation on Osteoarthritis. London: H.K. Lewis; 1893.; Алексеева ЛИ, Таскина ЕА, Кашеварова НГ. Остеоартрит: эпидемиология, классификация, факторы риска и прогрессирования, клиника, диагностика, лечение. Современная ревматология. 2019;13(2):9-21. doi:10.14412/1996-7012-2019-2-9-21; Лила АМ, Алексеева ЛИ, Таскина ЕА. Современные подходы к терапии остеоартрита с учетом обновленных международных рекомендаций. Русский медицинский журнал. Медицинское обозрение. 2019;3(11-2):48-52.; Veronese N, Cereda E, Maggi S, et al. Osteoarthritis and mortality: A prospective cohort study and systematic review with meta-analysis. Semin Arthritis Rheum. 2016 Oct;46(2):160-7. doi:10.1016/j.semarthrit.2016.04.002.; Kovari E, Kaposi A, Bekes G, et al. Comorbidity clusters in generalized osteoarthritis among female patients: A crosssectional study. Semin Arthritis Rheum. 2019 Sep 9. pii: S0049-0172(19)30233-1. doi:10.1016/j.semarthrit.2019.09.001.; Adler E, Wolf E, Taustein I. A double blind trial with cartilage and bone marrow extract in degenerative gonarthrosis. Acta Rheumatol Scand. 1970;16(1):6-11.; Katona G. A clinical trial of glycosaminoglycan-peptide complex (Rumalon) in patients with osteoarthritis of the knee. Curr Med Res Opin. 1987;10(9):625-33. doi:10.1185/03007998709112416.; Gramajo RJ, Cutroneo EJ, Fernandez DE, et al. A single-blind, placebo-controlled study of glycosaminoglycan-peptide complex (Rumalon) in patients with osteoarthritis of the hip or knee. Curr Med Res Opin. 1989; 11(6): 366-73. doi:10.1185/03007998909110137.; Алексеева ЛИ, Карякин АН, Смирнов АВ, Беневоленская ЛИ. Применение Румалона при гонартрозе. Терапевтический архив. 1997;(5):64-6.; Наумов АВ, Ткачева ОН, Котовская ЮВ, Ховасова НО. Эффективность и безопасность гликозаминогликанпептидного комплекса в терапии обострений хронической боли при остеоартрите коленных суставов у коморбидных больных (результаты наблюдательной программы ДАРТС). Лечащий врач. 2018;(7):2-7.; Каратеев АЕ, Алексеева ЛИ, Лила АМ и др. Оценка эффективности и безопасности гликозаминогликан-пептидного комплекса при лечении остеоартрита коленного сустава у больных с предшествующей неэффективностью пероральных медленно действующих противовоспалительных препаратов (многоцентровое открытое исследование ПРИМУЛА: Применение Румалона® при Исходно Малом Успехе в Лечении остеоАртрита). Научнопрактическая ревматология. 2018; 56(1):22-7.; Алексеева ЛИ, Каратеев АЕ, Погожева ЕЮ и др. Оценка эффективности и безопасности инъекционной формы гликозаминогликан-пептидного комплекса у пациентов с остеоартритом: многоцентровое наблюдательное исследование ГЛАДИОЛУС (ГПК при Лечении остеоАртрита: Динамическое Исследование Обезболивания и Локального Уменьшения Симптомов). Современная ревматология. 2020;14(2):76–83. doi:10.14412/1996-7012-2020-2-76-83.; Schacht E, Roetz R. Answer: Nephrotic syndrome after injections of bovine cartilage and marrow extract. Lancet. 1989 Apr 29; 1(8644):963. doi:10.1016/s0140-6736(89)92547-6.; https://mrj.ima-press.net/mrj/article/view/1089

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1089
https://doi.org/10.14412/1996-7012-2021-1-51-59

المؤلفون: A. M. Lila, L. I. Alekseeva, A. R. Babaeva, I. Z. Gaydukova, G. Gandolini, E. V. Zonova, R. Capelli, A. E. Karateev, S. S. Kopenkin, N. A. Martusevich, O. B. Nesmeyanova, E. N. Otteva, F. Rannuе, T. A. Raskina, M. L. Sukhareva, E. A. Taskina, N. V. Chichasova, S. P. Yakupova, А. М. Лила, Л. И. Алексеева, А. Р. Бабаева, И. З. Гайдукова, Г. Гандолини, Е. В. Зонова, Р. Капелли, А. Е. Каратеев, С. С. Копенкин, Н. А. Мартусевич, О. Б. Несмеянова, Э. Н. Оттева, Ф. Ранню, Т. А. Раскина, М. Л. Сухарева, Е. А. Таскина, Н. В. Чичасова, С. П. Якупова

المساهمون: Публикация статьи поддержана АО «Байер».

المصدر: Modern Rheumatology Journal; Том 13, № 4 (2019); 143-147 ; Современная ревматология; Том 13, № 4 (2019); 143-147 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2019-4

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/973/934; Bruyere O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019 Apr 30. pii: S0049-0172(19)30043-5. doi:10.1016/j.semarthrit.2019.04.008. [Epub ahead of print]; Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019 Jul 3. pii: S1063-4584(19)31116-1. doi:10.1016/j.joca.2019.06.011. [Epub ahead of print]; Ребров АП, Насонова ВА, Якушин СС и др. Итоги многоцентрового клинического исследования препарата Структум в России. Терапевтический архив. 2001;(11): 84-7.; Lippiello L. Collagen Synthesis in Tenocytes, Ligament Cells and Chondrocytes Exposed to a Combination of Glucosamine HCl and Chondroitin Sulfate. Evid Based Complement Alternat Med. 2007 Jun;4(2): 219-24. Epub 2006 Dec 1.; Clegg et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006 Feb 23; 354(8):795-808.; Hochberg MC, Martel-Pelletier J, Monfort J, et al; MOVES Investigation Group. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, noninferiority trial versus celecoxib. Ann Rheum Dis. 2016 Jan;75(1):37-44. doi:10.1136/annrheumdis-2014-206792. Epub 2015 Jan 14.; Martel-Pelletier J, Roubille C, Abram F, et al. First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort. Ann Rheum Dis. 2015 Mar;74(3):547-56. doi:10.1136/annrheumdis-2013-203906; Fransen M, Agaliotis M, Nairn L, et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis. 2015 May;74(5):851-8. doi:10.1136/annrheumdis-2013-203954. Epub 2014 Jan 6.; Zeng C, Wei J, Li H, et al. Effectiveness and safety of Glucosamine, chondroitin, the two in combination, or celecoxib in the treatment of osteoarthritis of the knee. Sci Rep. 2015 Nov 18;5:16827. doi:10.1038/srep16827.; Алексеева ЛИ, Шарапова ЕП, Кашеварова НГ и др. Многоцентровое проспективное наблюдательное исследование по применению препаратов АРТРА МСМ Форте и АРТРА у пациентов с остеоартритом коленных и/или тазобедренных суставов и/или с болью в нижней части спины (предварительные результаты). Трудный пациент. 2018;(16):34-41.; Кезля ОП. Комбинированное лечение остеоартроза коленного сустава. Медицинские новости. 2007;(7):85-7.; Garcia Rodriguez LA, Tacconelli S, Patrignani P. Role of Dose Potency in the Prediction of Risk of Myocardial Infarction Associated With Nonsteroidal Anti-Inflammatory Drugs in the General Population. J Am Coll Cardiol. 2008 Nov 11; 52(20):1628-36. doi:10.1016/j.jacc.2008.08.041.; McGettiganP, HenryD. CardiovascularRiskwithNon-SteroidalAnti-InflammatoryDrugs: SystematicReviewofPopulation-BasedControlledObservational Studies. PLoS Med. 2011 Sep;8(9):e1001098. doi:10.1371/journal.pmed.1001098. Epub 2011 Sep 27.; https://mrj.ima-press.net/mrj/article/view/973

الاتاحة: https://mrj.ima-press.net/mrj/article/view/973
https://doi.org/10.14412/1996-7012-2019-4-143-147

المؤلفون: L. N. Denisov, E. S. Tsvetkova, G. Sh. Golubev, O. V. Bugrova, I. S. Dydykina, A. I. Dubikov, L. V. Menshikova, L. K. Peshekhonova, A. P. Rebrov, A. N. Torgashin, E. A. Trofimov, S. P. Yakupova, E. V. Zonova, O. Brewer, C. Cooper, J. Reginster, L. A. Knyazeva, Л. Н. Денисов, Е. С. Цветкова, Г. Ш. Голубев, О. В. Бугрова, И. С. Дыдыкина, А. И. Дубиков, Л. В. Меньшикова, Л. К. Пешехонова, А. П. Ребров, А. Н. Торгашин, Е. А. Трофимов, С. П. Якупова, Е. В. Зонова, О. Брюйер, С. Купер, Ж. Реджинстер, Л. А. Князева

المصدر: Rheumatology Science and Practice; Vol 54, No 6 (2016); 641-653 ; Научно-практическая ревматология; Vol 54, No 6 (2016); 641-653 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20166

مصطلحات موضوعية: симптоматические препараты замедленного действия для лечения остеоартрита, non-steroidal anti-inflammatory drugs, patented crystalline glucosamine sulfate, knee osteoarthritis, symptomatic slow-acting drugs for osteoarthritis, гиалуроновая кислота, нестероидные противовоспалительные препараты, запатентованный кристаллический глюкозамина сульфат

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2317/1522; https://rsp.mediar-press.net/rsp/article/view/2317/1535; Балабанова РМ, Эрдес ШФ. Динамика распространенности ревматических заболеваний, входящих в XIII класс МКБ-10, в популяции взрослого населения Российской Федерации за 2000–2010 гг. Научно-практическая ревматология. 2012;50(3):10-2 [Balabanova RM, Erdes Sh F. Trends in prevalence of rheumatic diseases in ICD-10 adult population of the Russian Federation over 2000-2010. Nauchno- Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(3):10-2 (In Russ.)]. doi:10.14412/1995-4484-2012-702; Балабанова РМ, Эрдес ШФ. Распространенность ревматических заболеваний в России в 2012–2013 гг. Научно-практическая ревматология. 2015;53(2):120-4 [Balabanova RM, Erdes ShF. The incidence and prevalence of rheumatic diseases in Russia in 2012-2013. Nauchno- Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(2):120-4 (In Russ.)]. doi:10.14412/1995-4484-2015-120-124; Фоломеева OM, Галушко ЕА, Эрдес ШФ. Распространенность ревматических заболеваний в популяциях взрослого населения России и США. Научно- практическая ревматология. 2008;46(4):4-13 [Folomeeva OM, Galushko EA, Erdes SF. Prevalence of rheumatic diseases in adult populations of Russian Federation and USA. Nauchno- Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2008;46(4):4-13 (In Russ.)]. doi:10.14412/1995-4484-2008-529; Bruyere O, Cooper C, Pelletier JP, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014;44(3):253-63. doi:10.1016/j.semarthrit.2014.05.014; Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62(12):1145-55. doi:10.1136/ard.2003.011742; Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res. 2012;64(4):465-74. doi:10.1002/acr.21596; McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014;22(3):363-88. doi:10.1016/j.joca.2014.01.003; National Clinical Guideline Centre. Osteoarthritis care and management in adults: Methods, evidence and recommendations. London, UK: National Institute for Health and Care Excellence; 2014 February. Report No.: CG177.; Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2010;18(4):476-99. doi:10.1016/j.joca.2010.01.013; Da Costa BR, Reichenbach S, Keller N, et al. Effectiveness of non-steroidal anti- inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2016 May 21;387(10033):2093-105. doi:10.1016/S0140-6736(16)30002-2. Epub 2016 Mar 18.; Roberts E, Delgado Nunes V, Buckner S, et al. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis. 2016;75(3):552-9. doi:10.1136/annrheumdis-2014-206914; Kahan A, Uebelhart D, de Vathaire F, et al. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two- year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2009;60(2):524- 33. doi:10.1002/art.24255; Martel-Pelletier J, Pelletier JP. Effects of diacerein at the molecular level in the osteoarthritis disease process. Ther Adv Musculoskelet Dis. 2010;2(2):95-104. doi:10.1177/1759720X09359104; Dougados M, Nguyen M, Berdah L, et al. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip. Arthritis Rheum. 2001;44(11):2539-47. doi:10.1002/1529-0131(200111)44:113.0.CO;2-T; Maheu E, Mazieres B, Valat JP, et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial with a six-month treatment period and a two-month followup demonstrating a persistent effect. Arthritis Rheum. 1998;41(1):81-91. doi:10.1002/1529-0131(199801)41:13.0.CO;2-9; Pavelka K, Bruyere O, Cooper C, et al. Diacerein: benefits, risks and place in the management of osteoarthritis. An opinion-based report from the ESCEO. Drugs Aging. 2016;33(2):75-85. doi:10.1007/s40266-016-0347-4; Fidelix TS, Macedo CR, Maxwell LJ, et al. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2014;2:CD005117. doi:10.1002/14651858.cd005117.pub3; De Wan M, Volpi G, inventors; Rottapharm, assignee. Method of preparing mixed glucosamine salts. USA patent 5,847,107. 1998.; Towheed TE, Maxwell L, Anastassiades TP, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2009(2):CD002946.; Reginster JY. The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest. Arthritis Rheum. 2007;56(7):2105-10. doi:10.1002/art.22852; Eriksen P, Bartels EM, Altman RD, et al. Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: a meta- analysis of placebocontrolled trials. Arthritis Care Res (Hoboken). 2014;66(12):1844-55. doi:10.1002/acr.22376; Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001;357(9252):251-6. doi:10.1016/S0140-6736(00)03610-2; Pavelka K, Gatterova J, Olejarova M, et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2002;162(18):2113-23. doi:10.1001/archinte.162.18.2113; Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354(8):795-808. doi:10.1056/NEJMoa052771; Hochberg MC, Martel-Pelletier J, Monfort J, et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non- inferiority trial versus celecoxib. Ann Rheum Dis. 2016;75:37-44. doi:10.1136/annrheumdis- 2014-206792; Fransen M, Agaliotis M, Nairn L, et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo- controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis. 2015;74(5):851-8. doi:10.1136/annrheumdis- 2013-203954; Martel-Pelletier J, Roubille C, Abram F, et al. First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort. Ann Rheum Dis. 2015;74(3):547-56. doi:10.1136/annrheumdis-2013-203906; Persiani S, Rovati LC, Pastorini E, et al. Pharmacokinetics of glucosamine in man after oral administration of crystalline glucosamine sulfate or glucosamine hydrochloride alone or incombination with chondroitin sulfate. Osteoarthritis Cartilage. 2007;15(Suppl. C):C223. doi:10.1016/S1063-4584(07)62043-3; Altman RD. Glucosamine therapy for knee osteoarthritis: pharmacokinetic considerations. Expert Rev Clin Pharmacol. 2009;2(4):359-71. doi:10.1586/ecp.09.17; Bruyere O, Pavelka K, Rovati LC, et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartilage. 2008;16(2):254-60. doi:10.1016/j.joca.2007.06.011; Persiani S, Roda E, Rovati LC, et al. Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis Cartilage. 2005;13(12):1041-9. doi:10.1016/j.joca.2005.07.009; Jackson CG, Plaas AH, Sandy JD, et al. The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination. Osteoarthritis Cartilage. 2010;18(3):297-302. doi:10.1016/j.joca.2009.10.013; Persiani S, Rotini R, Trisolino G, et al. Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose. Osteoarthritis Cartilage. 2007;15(7):764-72. doi:10.1016/j.joca.2007.01.019; Chiusaroli R, Piepoli T, Zanelli T, et al. Experimental pharmacology of glucosamine sulfate. Int J Rheumatol. 2011;2011:939265. doi:10.1155/2011/939265; Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M, et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo- controlled study using acetaminophen as a side comparator. Arthritis Rheum. 2007;56(2):555-67. doi:10.1002/art.22371; Bjordal JM, Ljunggren AE, Klovning A, et al. Non-steroidal antiinflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ. 2004;329(7478):1317. doi:10.1136/bmj.38273.626655.63; Altman RD, Abadie E, Avouac B, et al. Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis. Osteoarthritis Cartilage. 2005;13(1):13-9. doi:10.1016/j.joca.2004.10.012; Cooper C, Adachi JD, Bardin T, et al. How to define responders in osteoarthritis. Curr Med Res Opin. 2013;29(6):719-29. doi:10.1185/03007995.2013.792793; Setnikar I, Rovati LC. Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. Arzneimittelforschung. 2001;51(9):699-725.; Reichelt A, Forster KK, Fischer M, et al. Efficacy and safety of intramuscular glucosamine sulfate in osteoarthritis of the knee. A randomised, placebo-controlled, double-blind study. Arzneimittelforschung. 1994;44(1):75-80.; Цветкова ЕС, Иониченок НГ, Денисов ЛН. Современная фармакотерапия остеоартроза коленных суставов: особенности симптоматического и болезнь-модифицирующего действия. Сообщение 1. Особенности симптоматического действия современных препаратов при остеоартрозе коленных суставов. Научно- практическая ревматология. 2015;53(1):63-8. [Tsvetkova ES, Ionichenok NG, Denisov LN. Current pharmacology for knee osteoarthritis: specific features of symptomatic and disease modifying effects. Communication 1. Specific features of the symptomatic effects of current drugs to treat knee osteoarthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(1):63-8 (In Russ.)]. doi:10.14412/1995-4484- 2015-63-68; Rovati LC, Girolami F, D’Amato M, et al. Effects of glucosamine sulfate on the use of rescue non-steroidal anti-inflammatory drugs in knee osteoarthritis: results from the Pharmaco-Epidemiology of GonArthroSis (PEGASus) study. Semin Arthritis Rheum. 2016;45(4 Suppl.):S34-S41. doi:10.1016/j.semarthrit.2015.10.009; Scholtissen S, Bruyere O, Neuprez A, et al. Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with paracetamol. Int J Clin Pract. 2010;64(6):756- 62. doi:10.1111/j.1742-1241.2010.02362.x; Palma Dos Reis R, Giacovelli G, Girolami F, et al. Crystalline glucosamine sulfate in the treatment of osteoarthritis: evidence of long-term cardiovascular safety from clinical trials. Open Rheumatol J. 2011;5:69-77. doi:10.2174/1874312901105010069; Chou R, McDonagh MS, Nakamoto E, et al. Analgesics for Osteoarthritis: An Update of the 2006 Comparative Effectiveness Review. October 2011. Rockville MD. Available from: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0016485/pdf/TOC.pdf. Last accessed June 1, 2016.; Lin J, Zhang W, Jones A, et al. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: metaanalysis of randomised controlled trials. BMJ. 2004;329(7461):324. doi:10.1136/bmj.38159.639028.7C; Tugwell PS, Wells GA, Shainhouse JZ. Equivalence study of a topical diclofenac solution (pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol. 2004;31(10):2002-12.; Simon LS, Grierson LM, Naseer Z, et al. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain. 2009;143(3):238-45. doi:10.1016/j.pain.2009.03.008; Цветкова ЕС, Панасюк ЕЮ, Иониченок НГ. Глюкозамин сульфат (дона) в терапии гонартроза: возможности и перспективы. Научно-практическая ревматология. 2004;42(2):7 [Tsvetkova ES, Panasyuk EY, Ionichenok NG. Glucosamine sulfate (Dona) in the treatment of gonarthrosis: possibilities and perspectives. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2004;42(2):7 (In Russ.)].; Pelster B. Osteoarthritis of the knee: percutaneous vs. oral treatment. In: Pelster B, editor. Topics in Arthritis and Rheumatism. Philadelphia: Lippincott-Raven; 1995. P. 9-12.; Underwood M, Ashby D, Cross P, et al. Advice to use topical or oral ibuprofen for chronic knee pain in older people: randomised controlled trial and patient preference study. BMJ. 2008;336(7636):138-42. doi:10.1136/bmj.39399.656331.25; Rechziegler H. Perkutane Therapie mit nicht-steroidalen Antiphlogistika. Therapiewoche. 1986;36:4674-83.; Walde HJ. Konzentration von Etofenamat in intra- und periartikulä ren Geweben nach perkutaner Applikation beim Menschen. Topische Behandlung mit nichtsteroidalen Antirheumatika. 4. Int. Etofenamat-Symposium vom 18.-21.6.1987 in Stresa, Italien: pmi-Verlag Frankfurt/Main: Der neue Weg; 1987. P. S91-4.; Pincus T, Koch G, Lei H, et al. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis. 2004;63(8):931-9. doi:10.1136/ard.2003.020313; Henry D, McGettigan P. Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs. Int J Clin Pract Suppl. 2003;(135):43-9.; Garcia Rodriguez LA, Hernandez-Diaz S. The risk of upper gastrointestinal complications associated with nonsteroidal antiinflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res. 2001;3(2):98-101. doi:10.1186/ar146; Chou CT, Tsai YY. A double-blind, randomized, controlled parallel group study evaluating the efficacy and safety of acemetacin for the management of osteoarthritis. Int J Clin Pharm Res. 2002;12(1):1-6.; Leeb BF, Bucsi L, Keszthelyi B. Behandlung der gonarthrose. Wirksamkeit und verträ glichkeit von retardiertem acemetacin im vergleich zu celecoxib. Orthopede. 2004;33:1032- 41.; Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012;35(12):1127-46. doi:10.1007/BF03261999; Freston JW. Rationalizing cyclooxygenase (COX) inhibition for maximal efficacy and minimal adverse events. Am J Med. 1999;107(6A):78S-88S. doi:10.1016/S0002-9343(99)00371-X; Lipani JA, Poland M. Clinical update of the relative safety of nabumetone in long-term clinical trials. Inflammopharmacology. 1995;3:351-61. doi:10.1007/BF02668031; Singh G. Gastrointestinal complications of prescription and overthe-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System. Am J Ther. 2000;7(2):115-21. doi:10.1097/00045391-200007020-00008; Hunt RH, Barkun AN, Baron D, et al. Recommendations for the appropriate use of anti- inflammatory drugs in the era of the coxibs: defining the role of gastroprotective agents. Can J Gastroenterol. 2002;16(4):231-40. doi:10.1155/2002/516092; Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a doubleblind, randomised trial. Lancet. 2007;369(9573):1621-6. doi:10.1016/S0140- 6736(07)60749-1; Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non- steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769-79. doi:10.1016/S0140- 6736(13)60900-9; Olsen AM, Fosbol EL, Lindhardsen J, et al. Long-term cardiovascular risk of nonsteroidal anti-inflammatory drug use according to time passed after first-time myocardial infarction: a nationwide cohort study. Circulation. 2012;126(16):1955-63. doi:10.1161/CIRCULATIONAHA.112.112607; Bellamy N, Campbell J, Robinson V, et al. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006(2):CD005321. doi:10.1002/14651858.cd005321.pub2; Waddell DD, Bricker DC. Total knee replacement delayed with Hylan G-F 20 use in patients with grade IV osteoarthritis. J Manag Care Pharm. 2007;13(2):113-21. doi:10.18553/jmcp.2007.13.2.113; Mar J, Romero Jurado M, Arrospide A, et al. [Cost-analysis of viscosupplementation treatment with hyaluronic acid in candidate knee replacement patients with osteoarthritis]. Rev Esp Cir Ortop Traumatol. 2013;57(1):6-14 (In Span.). doi:10.1016/j.recot.2012.08.006; Altman R, Lim S, Steen RG, et al. Correction: Hyaluronic acid injections are associated with delay of total knee replacement surgery in patients with knee osteoarthritis: Evidence from a Large U.S. Health Claims Database. PLoS One. 2016;11(1):e0148591. doi:10.1371/journal.pone.0148591; Bannuru RR, Schmid CH, Kent DM, et al. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015;162(1):46-54. doi:10.7326/M14-1231; Bannuru RR, Vaysbrot EE, Sullivan MC, et al. Relative efficacy of hyaluronic acid in comparison with NSAIDs for knee osteoarthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;43(5):593-9. doi:10.1016/j.semarthrit.2013.10.002; Miller LE, Block JE. US-approved intra-articular hyaluronic acid injections are safe and effective in patients with knee osteoarthritis: Systematic review and meta-analysis of randomized, salinecontrolled trials. Clin Med Insights Arthritis Musculoskelet Disord. 2013;6:57-63.; Bannuru RR, Natov NS, Dasi UR, et al. Therapeutic trajectory following intra-articular hyaluronic acid injection in knee osteoarthritis – meta-analysis. Osteoarthritis Cartilage. 2011;19(6):611-9. doi:10.1016/j.joca.2010.09.014; Bannuru RR, Natov NS, Obadan IE, et al. Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee osteoarthritis: a systematic review and meta- analysis. Arthritis Rheum. 2009;61(12):1704-11. doi:10.1002/art.24925; Karlsson J, Sjogren LS, Lohmander LS. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicentre study. Rheumatology (Oxford). 2002;41(11):1240-8. doi:10.1093/rheumatology/41.11.1240; Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2006;14(2):154-62. doi:10.1016/j.joca.2005.09.003; Juni P, Reichenbach S, Trelle S, et al. Efficacy and safety of intraarticular hylan or hyaluronic acids for osteoarthritis of the knee: a randomized controlled trial. Arthritis Rheum. 2007;56(11):3610-9. doi:10.1002/art.23026; Pavelka K, Uebelhart D. Efficacy evaluation of highly purified intra-articular hyaluronic acid (Sinovial(R) vs hylan G-F20 [Synvisc(R)]) in the treatment of symptomatic knee osteoarthritis. A double-blind, controlled, randomized, parallel-group noninferiority study. Osteoarthritis Cartilage. 2011;19(11):1294-300. doi:10.1016/j.joca.2011.07.016; Maheu E, Zaim M, Appelboom T, et al. Comparative efficacy and safety of two different molecular weight (MW) hyaluronans F60027 and Hylan G-F20 in symptomatic osteoarthritis of the knee (KOA). Results of a non inferiority, prospective, randomized, controlled trial. Clin Exp Rheumatol. 2011;29(3):527-35.; Reichenbach S, Blank S, Rutjes AW, et al. Hylan versus hyaluronic acid for osteoarthritis of the knee: a systematic review and meta-analysis. Arthritis Rheum. 2007;57(8):1410-8. doi:10.1002/art.23103; Bagga H, Burkhardt D, Sambrook P, et al. Longterm effects of intraarticular hyaluronan on synovial fluid in osteoarthritis of the knee. J Rheumatol. 2006;33(5):946-50.; Ghosh P, Guidolin D. Potential mechanism of action of intraarticular hyaluronan therapy in osteoarthritis: are the effects molecular weight dependent? Semin Arthritis Rheum. 2002;32(1):10-37. doi:10.1053/sarh.2002.33720; Pozo MA, Balazs EA, Belmonte C. Reduction of sensory responses to passive movements of inflamed knee joints by hylan, a hyaluronan derivative. Exp Brain Res. 1997;116(1):3-9. doi:10.1007/PL00005742; Smith MM, Ghosh P. The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of the hyaluronate in the extracellular environment. Rheumatol Int. 1987;7(3):113- 22. doi:10.1007/BF00270463; Aviad AD, Houpt JB. The molecular weight of therapeutic hyaluronan (sodium hyaluronate): how significant is it? J Rheumatol. 1994;21(2):297-301.; Berenbaum F, Grifka J, Cazzaniga S, et al. A randomised, double-blind, controlled trial comparing two intra-articular hyaluronic acid preparations differing by their molecular weight in symptomatic knee osteoarthritis. Ann Rheum Dis. 2012;71(9):1454-60. doi:10.1136/annrheumdis-2011-200972; Голубев ГШ, Голубев ВГ, Евсеев ОА и др. Результаты клинического испытания нового протеза синовиальной жидкости GO-ON®. Травматология и ортопедия России. 2007;44(2):48-56 [Golubev G, Golubev V, Evseev O, et al. The results of clinical investigation of new synovial fluid prosthesis Go-On®. Travmatologiya i Ortopediya Rossii = Traumatology and Orthopedics of Russia. 2007;44(2):48-56 (In Russ.)].; Hochberg MC, Wohlreich M, Gaynor P, et al. Clinically relevant outcomes based on analysis of pooled data from 2 trials of duloxetine in patients with knee osteoarthritis. J Rheumatol. 2012;39(2):352-8. doi:10.3899/jrheum.110307; Risser RC, Hochberg MC, Gaynor PJ, et al. Responsiveness of the Intermittent and Constant Osteoarthritis Pain (ICOAP) scale in a trial of duloxetine for treatment of osteoarthritis knee pain. Osteoarthritis Cartilage. 2013;21(5):691-4. doi:10.1016/j.joca.2013.02.007; Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923. doi:10.2165/00003088-200443130-00004; Langley PC, Patkar AD, Boswell KA, et al. Adverse event profile of tramadol in recent clinical studies of chronic osteoarthritis pain. Curr Med Res Opin. 2010;26(1):239-51. doi:10.1185/03007990903426787; Gana TJ, Pascual ML, Fleming RR, et al. Extended-release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Curr Med Res Opin. 2006;22(7):1391-401. doi:10.1185/030079906X115595; Cepeda MS, Camargo F, Zea C, et al. Tramadol for osteoarthritis. Cochrane Database Syst Rev. 2006(3):CD005522. doi:10.1002/14651858.cd005522.pub2; Roth SH. Efficacy and safety of tramadol HCl in breakthrough musculoskeletal pain attributed to osteoarthritis. J Rheumatol. 1998;25(7):1358-63.; Raber M, Schulz HU, Schurer M, et al. Pharmacokinetic properties of tramadol sustained release capsules. 3rd communication: investigation of relative bioavailability under steady state conditions. Arzneimittelforschung. 1999;49(7):594-8.; Cnota PJ, Nowak H, Tagarro I, et al. Tramadol SR formulations: Pharmacokinetic comparison of a multiple-units dose (capsule) versus a single-unit dose (tablet). Clin Drug Investig. 2005;25(7):435-43. doi:10.2165/00044011-200525070-00002; Tagarro I, Herrera J, Barutell C, et al. Effect of a simple doseescalation schedule on tramadol tolerability : assessment in the clinical setting. Clin Drug Investig. 2005;25(1):23- 31. doi:10.2165/00044011-200525010-00003; Ethgen O, Bruyere O, Richy F, et al. Health-related quality of life in total hip and total knee arthroplasty. A qualitative and systematic review of the literature. J Bone Joint Surg Am. 2004;86- A(5):963-74. doi:10.2106/00004623-200405000-00012; Griffin T, Rowden N, Morgan D, et al. Unicompartmental knee arthroplasty for the treatment of unicompartmental osteoarthritis: a systematic study. ANZ J Surg. 2007;77(4):214-21. doi:10.1111/j.1445-2197.2007.04021.x; Murray DW, Liddle AD, Dodd CA, et al. Unicompartmental knee arthroplasty: is the glass half full or half empty? Bone Joint J. 2015;97-B(10 Suppl A):3-8. doi:10.1302/0301-620X.97B10.36542; Lutzner J, Kasten P, Gunther KP, et al. Surgical options for patients with osteoarthritis of the knee. Nat Rev Rheumatol. 2009;5(6):309-16. doi:10.1038/nrrheum.2009.88; Sanders JO, Bozic KJ, Glassman SD, et al. Clinical practice guidelines: their use, misuse, and future directions. J Am Acad Orthop Surg. 2014;22(3):135-44. doi:10.5435/JAAOS-22- 03-135; Brouwer RW, Huizinga MR, Duivenvoorden T, et al. Osteotomy for treating knee osteoarthritis. Cochrane Database Syst Rev. 2014;12:CD004019. doi:10.1002/14651858.cd004019.pub4; Loveday D, Clifton R, Robinson A. Interventions for treating osteochondral defects of the talus in adults. Cochrane Database Syst Rev. 2010(8):CD008104. doi:10.1002/14651858.cd008104.pub2; Vasiliadis HS, Wasiak J. Autologous chondrocyte implantation for full thickness articular cartilage defects of the knee. Cochrane Database Syst Rev. 2010(10):CD003323. doi:10.1002/14651858.cd003323.pub3; Randsborg PH, Brinchmann J, Loken S, et al. Focal cartilage defects in the knee – a randomized controlled trial comparing autologous chondrocyte implantation with arthroscopic debridement. BMC Musculoskelet Disord. 2016;17(1):117. doi:10.1186/s12891-016-0969-z; Голубев ВШ, Кролевец ИВ, Жданов ВГ. Сравнительная характеристика методов лечения дефектов суставного хряща коленного сустава. New Medical Technologies. 2008:5. Доступно по ссылке: http://www.mst.ru/publications/rus/NewMedTechno_2008.pdf [Golubev GS, Kropevets IV, Zhdanov VG, et al. Comparative characteristics of methods of treatment of articular cartilage defects of the knee. New Medical Technologies. 2008:5. Available from: http://www.mst.ru/publications/rus/NewMedTechno_2008.pdf].; Голубев ГШ, Кролевец ИВ, Голубев ВГ. Сравнение эффективности малоинвазивных методов пластики дефектов суставного хряща коленного сустава. Доступно по ссылке: http://bone- surgery.ru/view/sravnenie_effektivnosti_maloinvazivnyh_metodov_plastiki_defektov_susta vnogo/ [Golubev G, Krolevetz I, Golubev V. Comparison of the effectiveness of minimally invasive methods of plastic surgery for defects in the articular cartilage of the knee joint. Available from: http://bonesurgery.ru/view/sravnenie_effektivnosti_maloinvazivnyh_metodov_plastiki_defektov_sustavnogo/].; Da Costa BR, Nuesch E, Kasteler R, et al. Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev. 2014;9:CD003115. doi:10.1002/14651858.cd003115.pub4; https://rsp.mediar-press.net/rsp/article/view/2317

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2317
https://doi.org/10.14412/1995-4484-2016-641-653

المؤلفون: B. S. Belov, N. N. Kuzmina, L. G. Medyntseva, A. R. Babaeva, N. A. Shostak, E. V. Zhilyaev, S. E. Myasoedova, T. A. Raskina, S. P. Yakupova, V. N. Sorotskaya, E. N. Otteva, Б. С. Белов, Н. Н. Кузьмина, Л. Г. Медынцева, А. Р. Бабаева, Н. А. Шостак, Е. В. Жиляев, С. Е. Мясоедова, Т. А. Раскина, С. П. Якупова, В. Н. Сороцкая, Э. Н. Оттева

المصدر: Rheumatology Science and Practice; Vol 54, No 4 (2016); 395-397 ; Научно-практическая ревматология; Vol 54, No 4 (2016); 395-397 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20164

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2266/1474; Gewitz MH, Baltimore RS, Tani LY, et al. Revision of the Jones Criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography: a scientific statement from the American Heart Association. Circulation. 2015;131(20):1806-18. doi:10.1161/CIR.0000000000000205; Насонова ВА, Кузьмина НН, Белов БС. Классификация и номенклатура ревматической лихорадки. Научно-практическая ревматология. 2004;42(2):48-52 [Nasonova VA, Kuz'mina NN, Belov BS. Classification and nomenclature of rheumatic fever. Rheumatology Science and Practice = Nauchno-Prakticheskaya Revmatologiya. 2004;42(2):48-52 (In Russ.)].; https://rsp.mediar-press.net/rsp/article/view/2266

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2266
https://doi.org/10.14412/1995-4484-2016-395-397

المؤلفون: Tamila Nilovna Khalfina, I G Salikhov, S P Yakupova, Т. Н. Халфина, И. Г. Салихов, С. П. Якупова

المصدر: Modern Rheumatology Journal; Том 4, № 2 (2010); 62-65 ; Современная ревматология; Том 4, № 2 (2010); 62-65 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2010-2

مصطلحات موضوعية: Урисан, hyperuricemia, uric acid, Urisan, гиперурикемия, мочевая кислота

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/290/285; Барскова В.Г. Нимесулид в лечении подагрического артрита. Consilium Medicum 2008; 2(10): 19-23. Барскова В.Г. Подагра в XXI веке. Науч.-практич. ревматол. 2009; 2(Прил.): 44-6. Максудова А.Н., Салихов И.Г., Хабиров Р.А. В кн.: Подагра. М.: МЕДпресс-информ, 2008; 96. Lee H.Y., Ariyasinghe J.T.N., Thirumoorthy T. Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adversereaction? Singapore Med J 2008; 49(5): 384. Ильина А.Е., Барскова В.Г. Применение Урисана при подагре. Совр. ревматол. 2008; 1: 81-3. Мясоедова С.Е., Кожевникова Е.А. Новые возможности коррекции гиперурикемии при подагре. Совр. ревматол. 2009; 4: 37-9.; https://mrj.ima-press.net/mrj/article/view/290

الاتاحة: https://mrj.ima-press.net/mrj/article/view/290
https://doi.org/10.14412/1996-7012-2010-605